Related Experiment Videos
Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue
1Department of Oncology, University Hospital, Uppsala, Sweden.
Abstract:
Transforming growth factor beta (TGF-beta) is a family of proteins which act as a potent growth inhibitor for most cell types including epithelial cells. TGF-beta is synthesized as latent high molecular weight complexes, composed of TGF-beta, the NH2-terminal part of the TGF-beta precursor and the third molecule, the latent TGF-beta binding protein (LTBP). We here ascertain that TGF-beta is expressed in human prostatic cancer tissue as well as in cystectomized prostatic tissue and in materials from transurethral resections with benign prostatic hyperplasia, analyzed by immunohistochemistry. TGF-beta is observed in both epithelial cells and stromal cells. No significant correlation was obtained between TGF-beta expression in tumor cells and their degree of differentiation. However, analysis by immunohistochemistry using antibodies against LTBP revealed that specimens from histopathologically verified human prostatic cancer are mostly negative for this molecule, although it is expressed in cystectomized prostatic and benign prostatic hyperplasia tissues. These results indicate that in cystectomized prostatic and benign prostatic hyperplasia tissues, TGF-beta may be produced in a complex associated with LTBP; whereas in prostatic carcinoma, TGF-beta is produced without associating with LTBP. The biological significance of the production of TGF-beta in relation to LTBP and the possible association with prognosis are discussed.
Insights
Transforming growth factor beta (TGF-beta) is expressed in prostate tissues. In benign conditions, TGF-beta associates with latent TGF-beta binding protein (LTBP), but not in prostate cancer.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Transforming growth factor beta (TGF-beta) is a protein family that inhibits cell growth.
- TGF-beta is synthesized in latent complexes with LTBP.
- Understanding TGF-beta's role in prostate cancer is crucial.
Purpose of the Study:
- To investigate TGF-beta and LTBP expression in human prostate tissues.
- To determine if TGF-beta expression correlates with prostate cancer differentiation.
- To explore the association of TGF-beta and LTBP in benign and malignant prostate conditions.
Main Methods:
- Immunohistochemistry was used to analyze TGF-beta and LTBP expression.
- Prostate tissues examined included cancerous, cystectomized, and benign hyperplastic samples.
- Expression levels were assessed in both epithelial and stromal cells.
Main Results:
- TGF-beta was detected in epithelial and stromal cells across all examined prostate tissues.
- No significant correlation was found between TGF-beta expression and tumor cell differentiation.
- LTBP was predominantly absent in prostate cancer tissues but present in benign and cystectomized tissues.
Conclusions:
- TGF-beta may be produced without LTBP association in prostate carcinoma.
- In benign prostatic hyperplasia and cystectomized tissues, TGF-beta likely forms complexes with LTBP.
- Further research is needed to understand the biological significance and prognostic implications of TGF-beta and LTBP interactions in prostate cancer.